Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yuhan
Pharma
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Lilly is making a series of investments in China. Gilead ended a MASH deal with Yuhan. A study suggests Leqembi's vial design is wasteful.
Angus Liu
Oct 18, 2024 8:20am
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
Sep 27, 2024 10:15am
Gilead, Yuhan ink $81M HIV API supply pact
Sep 20, 2024 11:20am
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
J&J's Tagrisso challenger wins FDA nod in first-line lung cancer
Aug 20, 2024 10:26am
ESMO: Should AZ worry about J&J's Tagrisso head-to-head win?
Oct 23, 2023 10:30am
